London, United Kingdom
Peptone, founded in 2018, is a pioneering player in the Biotechnology and Pharmaceutical sectors, headquartered in the United Kingdom. Leveraging a unique combination of AI and experimental physics, Peptone has developed a product engine aimed at designing small molecules that can target the 6,200 intrinsically disordered proteins previously unmodelable by Alpha Fold 3.
With its slogan, "Drugging disordered proteins with physics and AI," the company addresses a significant gap in the drug discovery field. This innovative approach positions Peptone at the forefront of new therapeutic developments, targeting a challenging class of proteins with high medical relevance.
Peptone last attracted a $40.00M Series A investment on 09 June 2022, showcasing strong support from leading investors including Bessemer Venture Partners, F-Prime Capital, Hoxton Ventures, Walden Catalyst, and dRx Capital. This backing underscores investor confidence in the company's innovative strategy and potential impact on the pharmaceutical industry.
Denovo Sciences